2022/04/25
(SHANGHAI, April 25, 2022) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first quarter ending March 31, 2022 (“Reporting Period”).
Read more2022/04/08
SHANGHAI, April 8 2022 -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an ESG Risk Rating, recognizing it as a “Top Rated” performing company from Sustainalytics as of March, 2022. WuXi AppTec placed in the top 4 percent of the global pharmaceutical industry with a “Low Risk” of experiencing material financial impacts from ESG factors. The strong performance reflects its commitment to Environmental, Social and Governance (ESG) initiatives.
Read more2022/03/23
(SHANGHAI, March 23, 2022) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its annual results for the year ending December 31, 2021 (“Reporting Period”).
Read more2022/03/08
March 7, 2022 – Philadelphia. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™).
Read more2022/02/11
Shanghai, February 10, 2022 - WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, Compatibility, Expertise, Quality, Reliability and Service and scored as a 2022 CMO Leadership Award Champion in four core categories. It is the eighth year that WuXi STA has been selected as an award-winner and the third consecutive year recognized in all six core categories.
Read more